Back to Journals » Drug, Healthcare and Patient Safety » Volume 2

Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options

Authors Payer J, Brazdilova K, Jackuliak P

Published 20 May 2010 Volume 2010:2 Pages 49—59

DOI https://doi.org/10.2147/DHPS.S7197

Review by Single-blind

Peer reviewer comments 2


Juraj Payer, Kristina Brazdilova, Peter Jackuliak

5th Department of Internal Medicine, Medical Faculty of Comenius University and Faculty Hospital Bratislava, Bratislava, Slovakia

Abstract: An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis. Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures. In this review, we summarize the currently available methods of prevention and the treatment of glucocorticoid-induced osteoporosis. We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.

Keywords: glucocorticoid-induced osteoporosis, bone mineral density, osteoporotic fractures, calcium and vitamin D, bisphosphonates, teriparatide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]